Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis - Case Reports in Clinical Medicine

CRCM > Vol.7 No.5, May 2018

Case Reports in Clinical Medicine

Volume 7, Issue 5 (May 2018)

ISSN Print: 2325-7075 ISSN Online: 2325-7083

Google-based Impact Factor: 0.2 Citations

Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis ()

HTML XML

Download as PDF (Size: 368KB) PP. 324-342

DOI: 10.4236/crcm.2018.75030 1,378 Downloads 3,282 Views Citations

Author(s)

IsraaIsraa Ahmed Radwan^*, Nahed Sedky Korany, Bassant Adel Ezzat

Affiliation(s)

Department of Oral Biology, Faculty of Oral and Dental Medicine, Cairo University, Cairo, Egypt.

ABSTRACT

Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We review here two of the commonly used bisphosphonates zoledronate and alendronate.

KEYWORDS

Bisphosphonates, Alendronate, Zoledronate, Postmenopausal Osteoporosis

Share and Cite:

Radwan, I. , Korany, N. and Ezzat, B. (2018) Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis. Case Reports in Clinical Medicine, 7, 324-342. doi: 10.4236/crcm.2018.75030.

Cited by